Trial · NCT04254978

Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)

NCT04254978, Phase 2, Completed, Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA); results first posted 2024-04-02

3 sourcestrials-2026-11-12-0.5.0

Download JSON

Cite this record

ConductScience Library. Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003). Trials, record NCT04254978. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT04254978

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Study of Bomedemstat in Participants With Essential Thrombocythemia (IMG-7289-CTP-201/MK-3543-003)
NCT number: NCT04254978
Status: Completed
Phases: Phase 2
Enrollment: 73 participants, actual
Lead sponsor: Imago BioSciences, Inc., a subsidiary of Merck & Co., Inc., (Rahway, New Jersey USA)
Conditions: Essential Thrombocythemia
Interventions: Bomedemstat
First posted: 2020-02-05
Last updated: 2026-05-04
Other registries' IDs: eudract:2019-003659-13
Results first posted: 2024-04-02

Source ClinicalTrials.gov

Registered outcomes3

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Number of Participants Who Experienced an Adverse Event (AE)	Up to approximately 30 months	An AE is any undesirable physical, psychological or behavioral effect experienced by a participant during the study, in conjunction with the use of the drug or biologic, whether or not product related. This includes any untoward signs or symptoms experienced by the participant from the time of first dose with study treatment until completion of the study. The number of participants who experienced an AE is reported.
Primary	Number of Participants Who Discontinued Study Treatment Due to an AE	Up to approximately 28 months	An AE is any undesirable physical, psychological or behavioral effect experienced by a patient during participation in the study, in conjunction with the use of the drug or biologic, whether or not product-related. This includes any untoward signs or symptoms experienced by the patient from the time of first dose with study treatment until completion of the study. The number of participants who discontinued study treatment due to an AE is reported.
Primary	Percentage of Participants With Platelet Count ≤400 k/μL at Day 169	Up to day 169	Blood samples were collected at pre-specified timepoints to determine platelet counts. The percentage of participants who achieved reduction in platelet count to ≤400k/μL in the absence of new thrombolytic events is reported.

Source ClinicalTrials.gov

Outcomes3

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Number of Participants Who Experienced an Adverse Event (AE)	Up to approximately 30 months	All participants who were enrolled in the study and received at least 1 dose of study drug	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Number of Participants Who Discontinued Study Treatment Due to an AE	Up to approximately 28 months	All participants who were enrolled in the study and received at least one dose of study drug	Participants	COUNT_OF_PARTICIPANTS
PRIMARY	Percentage of Participants With Platelet Count ≤400 k/μL at Day 169	Up to day 169	All participants who were enrolled in the study, received at least one dose of study drug, and had a non-missing baseline and at least 1 non-missing post-baseline efficacy assessment.	Percentage of Participants	NUMBER

Source ClinicalTrials.gov

Results by group3

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Value	Spread	Units
Number of Participants Who Experienced an Adverse Event (AE)	Bomedemstat	73		Participants
Number of Participants Who Discontinued Study Treatment Due to an AE	Bomedemstat	11		Participants
Percentage of Participants With Platelet Count ≤400 k/μL at Day 169	Bomedemstat	76.6	95% Confidence Interval 64.3 to 86.2	Percentage of Participants

Source ClinicalTrials.gov

Participant flow6

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Initial Treatment Period (ITP)	STARTED	Bomedemstat	73
Initial Treatment Period (ITP)	COMPLETED	Bomedemstat	64
Initial Treatment Period (ITP)	NOT COMPLETED	Bomedemstat	9
Additional Treatment Period (ATP)	STARTED	Bomedemstat	63
Additional Treatment Period (ATP)	COMPLETED	Bomedemstat	52
Additional Treatment Period (ATP)	NOT COMPLETED	Bomedemstat	11

Source ClinicalTrials.gov

Adverse events97

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk	Events
other	Anaemia	Blood and lymphatic system disorders	Bomedemstat	14	73	35
other	Neutropenia	Blood and lymphatic system disorders	Bomedemstat	8	73	12
other	Thrombocytopenia	Blood and lymphatic system disorders	Bomedemstat	23	73	47
other	Abdominal discomfort	Gastrointestinal disorders	Bomedemstat	4	73	4
other	Abdominal pain	Gastrointestinal disorders	Bomedemstat	6	73	7
other	Constipation	Gastrointestinal disorders	Bomedemstat	29	73	35
other	Diarrhoea	Gastrointestinal disorders	Bomedemstat	15	73	22
other	Dyspepsia	Gastrointestinal disorders	Bomedemstat	6	73	6
other	Flatulence	Gastrointestinal disorders	Bomedemstat	4	73	4
other	Gingival bleeding	Gastrointestinal disorders	Bomedemstat	6	73	6

1 to 10 of 97Source ClinicalTrials.gov

See all 97 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Bomedemstat	2	73
Total, other adverse events	Bomedemstat	72	73
Total, serious adverse events	Bomedemstat	27	73

Source ClinicalTrials.gov

Papers1

The papers the trial lists on ClinicalTrials.gov.

PMID	Listed as
41758981	RESULT

Source PubMed

Grants0

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

None in this release.

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT04254978

GET https://conductscience.org/api/trials/v1/NCT04254978/events?page=2

API reference For AI assistants